论文部分内容阅读
目的:探究结直肠癌(CRC)患者血浆中miR-221的临床价值。方法:收集60例正常健康体检志愿者(对照组),80例就诊我院的CRC患者(病例组),对所有入选者均进行血浆miR-221实时荧光定量聚合酶链反应(real time-PCR)检测。结果:(1)血浆miR-221含量在CRC组织较对照组表达明显升高(P<0.001),并随着duke分期的发展呈现递增的趋势(P<0.01)。(2)患者入院后均符合手术治疗条件,并于术后第7天复查miR-221含量,发现较治疗前明显减低(P<0.01)。3.对入院时CRC患者根据血浆miR-221相对值进行分组,miR-221高值组术后2年内发生癌复发的发生率高于低值组(P<0.001)。结论:血浆miR-221的测定有助于CRC的诊断,并对病情的估计和预后的判断有一定的帮助。
Objective: To investigate the clinical value of miR-221 in the plasma of patients with colorectal cancer (CRC). Methods: Sixty normal healthy volunteers (control group) and 80 CRC patients (case group) were enrolled in this study. Plasma miR-221 real time-PCR (real time-PCR) ) Test. Results: (1) The expression of plasma miR-221 in CRC tissue was significantly higher than that in the control group (P <0.001), and showed an increasing trend with the progression of duke staging (P <0.01). (2) Patients were admitted to hospital after surgery under the conditions of treatment, and in the first 7 days after the review of miR-221 content was significantly lower than before treatment (P <0.01). The incidence of cancer recurrence within 2 years after operation in the miR-221 high-value group was higher than that in the low-value group (P <0.001). Conclusion: The determination of plasma miR-221 is helpful for the diagnosis of CRC, and it is helpful to estimate the disease and prognosis.